04 June 2024
: Case report 
Rare Pathogens in Peritoneal Dialysis-Associated Peritonitis: A Comprehensive Case Study and Guideline Review
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease, Adverse events of drug therapy
Abbas Mohammadi1ABCDEF*, Hossein Akhondi1ADE, Dhiresh R. Joshi2DE, Seyed Abbas Mirabbasi1DEDOI: 10.12659/AJCR.943953
Am J Case Rep 2024; 25:e943953
Table 4. Recommended antibiotics and treatment duration guidelines for peritonitis according to causative organism.
| Organism | Antibiotic | Duration |
|---|---|---|
| Gram-positive coverage based on sensitivity or IP vancomycin if MRSA | 3 weeks | |
| IP cephazolin or IP vancomycin if MRSA | 2 weeks | |
| CRAB | IP amikacin or colistin ± ampicillin/sulbactam | 3 weeks |
| Coagulase-negative staphylococci | IP cephalosporin or vancomycin | 2 weeks |
| Corynebacterium | IP vancomycin | 2 weeks |
| Pseudomonas | IP ceftazidime or cefepime plus IP aminoglycoside | 3 weeks |
| Enterococcal | Oral amoxicillin (for ampicillin-susceptible enterococci) or IP vancomycin | 3 weeks |
| Enteric gram-negative | According to susceptibility | 3 weeks |
| CRAB – carbapenem-resistant ; IP – intraperitoneal; MRSA – methicillin-resistant. | ||